Empagliflozin (Jardiance) Dose for HFpEF
The recommended dose of empagliflozin for heart failure with preserved ejection fraction (HFpEF) is 10 mg once daily.
Evidence-Based Dosing
The 10 mg daily dose is firmly established across multiple high-quality guidelines and the pivotal EMPEROR-Preserved trial 1, 2, 3. This is a fixed dose—not a starting dose requiring titration. The FDA-approved labeling confirms empagliflozin 10 mg once daily for adults with heart failure regardless of ejection fraction 4.
Key Trial Data
In EMPEROR-Preserved, 5,988 patients with LVEF >40% received empagliflozin 10 mg daily versus placebo, demonstrating:
- 21% reduction in cardiovascular death or heart failure hospitalization (HR 0.79,95% CI 0.69-0.90) 1, 5
- 29% reduction in first heart failure hospitalization (HR 0.71,95% CI 0.60-0.83) 2
- Benefits consistent regardless of diabetes status 1, 6
- Median follow-up of 26.2 months 1, 5
Why Not 25 mg?
The 25 mg dose studied in type 2 diabetes trials was never evaluated in the HFpEF population. The EMPEROR-Preserved trial specifically used 10 mg daily, and this is the only dose with proven efficacy for heart failure outcomes 1, 2, 5. The most recent 2025 Canadian guidelines explicitly list empagliflozin 10 mg daily as both the starting and target dose for HFnrEF (which includes HFpEF) 7.
Practical Implementation
Initiation:
- Start 10 mg once daily immediately upon diagnosis
- No titration required
- Can be initiated in both inpatient and outpatient settings 3
Renal Considerations:
- Safe down to eGFR ≥20 mL/min/1.73 m² based on trial enrollment 1, 8, 4
- Contraindicated in patients on dialysis 4
- No dose adjustment needed for renal impairment above this threshold 4
Common Pitfalls to Avoid:
- Do not use the 25 mg dose for HFpEF—this lacks evidence and exceeds studied exposure levels 9
- Do not delay initiation waiting for "optimization" of other therapies—empagliflozin can be started early 8
- Do not discontinue in patients who develop mild eGFR decline—this is expected and reversible 4
Safety Profile
The 10 mg dose demonstrated favorable tolerability in HFpEF patients 1, 5:
- Increased genital and urinary tract infections (manageable)
- Mild hypotension risk (monitor in volume-depleted patients)
- No excess hypoglycemia in non-diabetic patients 6
- Temporary eGFR decline that stabilizes and reverses after discontinuation 4
Volume status assessment before initiation is critical—correct volume depletion first, especially in patients ≥75 years who have higher risk 4.
Guideline Consensus
The 2023 ACC Expert Consensus 3, 2023 ADA Standards 1, 2025 Canadian guidelines 7, and 2022 Canadian CCS/CHFS guidelines 2 all uniformly recommend empagliflozin 10 mg daily for HFpEF. This represents a Strong Recommendation with High-Quality Evidence across all major societies 7, 2.